ImmunoPrecise Antibodies Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA45257F2008
USD
2.07
0.32 (18.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About ImmunoPrecise Antibodies Ltd. stock-summary
stock-summary
ImmunoPrecise Antibodies Ltd.
Pharmaceuticals & Biotechnology
Immunoprecise Antibodies Ltd, formerly Tanqueray Exploration Ltd, is a Canada-based supplier of custom hybridoma development services. The Company's geographical segments include United States of America and Canada. It offers products, such as antibodies and hybridoma licensing. It offers various services, such as ImmunoProtect, Monoclonal Development, Polyclonal Development, Antibody Protection, Peptide Production and Cryopreservation Services. Its antibody products include IPA006A, IPA006B and IPA006F, which it offers to the research and industrial community. Its hybridoma licensing products include Anti-Human P38a (MAPKinase) Monoclonal Antibody Hybridoma Cell Line and Anti-Acetylated Lysine Monoclonal Antibody Hybridoma Cell Line. It offers cryopreservation storage service for the secure storage of users' valuable biological materials, including hybridoma clones, plasmid constructs and cell lines. It also offers both peptide synthesis and protein carrier conjugation services.
Company Coordinates stock-summary
Company Details
880 - 580 HORNBY STREET , VANCOUVER BC : V6C3B6
stock-summary
Tel: 1 604 80606261 438 8637071
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.08%)

Foreign Institutions

Held by 11 Foreign Institutions (0.69%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. James Kuo
Independent Chairman of the Board
Ms. Jennifer Bath
President, Chief Executive Officer, Director
Mr. Paul Andreola
Independent Director
Mr. Robert Beecroft
Independent Director
Mr. Robert Burke
Independent Director
Mr. Brian Lundstrom
Independent Director
Mr. Greg Smith
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Apr 2025)
Net Profit:
-2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 85 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.37

stock-summary
Return on Equity

-38.28%

stock-summary
Price to Book

4.99